GTx, Inc.
GTx Announces Investigational Ostarine MK-2866 Met the Primary Endpoint in the Phase II Cancer Cachexia Clinical Trial
Published in Women's Health Weekly, October 30th, 2008
GTx, Inc. (NASDAQ: GTXI) announced topline results of a Phase II clinical trial evaluating Ostarine(TM) (MK-2866), an investigational selective androgen receptor modulator (SARM), in patients with cancer induced muscle loss, also known as cancer cachexia. In this analysis, the study met its primary endpoint of absolute change in total lean body mass (muscle) compared to placebo and the secondary endpoint of muscle function (performance) after 16 weeks of treatment. GTx and Merck & Co., Inc. are collaborating to develop Ostarine and other SARMs, which are a new class of drugs with the potential to treat sarcopenia, which is the loss of skeletal muscle mass resulting in reduced physical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- American Academy of Neurology
Disease leads to vision loss more often in men - American Academy of Sleep Medicine
Association found among severe obstructive apnea, high fat diets, less physical activity in women - American Academy of Sleep Medicine
Insomnia in women with breast cancer linked to heart rate dysregulation - American Association for Cancer Research
Study links nicotine with breast cancer growth and spread - Hospital for Special Surgery
Statins may prevent miscarriages - London School of Hygiene & Tropical Medicine
People lacking vital antioxidants and exposed to sunlight more likely to develop AMD - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
